Logan Haak, MD
Retina Specialist · San Diego, CANPI 1952565491
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,075 of the $7,469 with a category attached, or 81.3%. It is spread thinly across 43 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,028 and has fallen 64.2% since, to $726 in 2025.
Across 239 payments — averaging $31.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Regeneron$1K
- GSK$538
- Regeneron Healthcare Solutions, Inc.$448
- EMD Serono, Inc.$297
- Theratechnologies Inc.$293
- plus $3K from 37 others
Across 8 payments — averaging $2766.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$15K
- AbbVie$7K
What the payments were for
- Consulting fees$1,37518%
- Food & beverage$6,07581%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,469 in reported general payments places this provider in the 65th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 31 | $791 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $361 |
| Latanoprost | 46 | $285 |
| Ofloxacin | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in San Diego
- Chirag ShahSan Diego$16K
- Thomas LazzariniSan Diego$15K
- Jason MossSan Diego$11K
- Delu SongSan Diego$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.